Rule 3.19A.2

# Appendix 3Y

# Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Noxopharm Limited (ASX: NOX)	
ABN	50 608 966 123	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Boris Patkin
Date of last notice	18 June 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	15 December 2020	
No. of securities held prior to change	DIRECT 1. 630,000 Ordinary shares 2. 60,000 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30	
Class	3. Unlisted Options, Exercisable @ the VWAP for the last 14 trading days on the ASX prior to the date of exercise in addition to a further 20% of that amount, Vesting in two different tranches and Expiry 14 December 2024.	

<sup>+</sup> See chapter 19 for defined terms.

Number acquired	3. 250,000 Unlisted Options, Exercisable @ the VWAP for the last 14 trading days on the ASX prior to the date of exercise in addition to a further 20% of that amount, Vesting in two different tranches and Expiry 14 December 2024.	
Number disposed	N/A	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Options granted for no consideration as part of director renumeration.	
No. of securities held after change	DIRECT1.630,000 Ordinary shares2.60,000 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30;3.250,000 Unlisted Options, Exercisable @ the VWAP for the last 14 trading days on the ASX prior to the date of exercise in addition to a further 20% of that amount, Vesting in two different tranches and Expiry 14 December 2024.	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	The securities are being issued as part of non- executive Director remuneration, as approved by Shareholders at the 2020 Annual General Meeting on 17 November 2020	

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>+</sup> See chapter 19 for defined terms.